[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657101":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":30,"studyPopulation":31,"armGroups":32,"interventions":26,"overallOfficials":36,"centralContacts":41,"locations":26,"responsibleParty":47,"collaborators":26,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":26,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":26,"enrollmentInfo":60,"targetDuration":26,"studyType":63,"phases":26,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":75,"whyStopped":26,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":26},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":26},[9],{"measure":10,"description":11,"timeFrame":12},"Prevalence of Pulmonary Hypertension in MPN Patients","PASP measured by echocardiography using TR velocity. Pulmonary hypertension defined as PASP greater than 35 mmHg or TR velocity greater than 2.8 m\u002Fs. Prevalence will be calculated.","Baseline",[14,17,20,23],{"measure":15,"description":16,"timeFrame":12},"Prevalence of right ventricular dysfunction","Proportion of patients with right ventricular dysfunction defined by TAPSE \\\u003C17 mm, RV fractional area change \\\u003C35%, or tissue Doppler S' \\\u003C9.5 cm\u002Fs",{"measure":18,"description":19,"timeFrame":12},"Pulmonary artery systolic pressure","Mean estimated pulmonary artery systolic pressure (mmHg) measured by echocardiography",{"measure":21,"description":22,"timeFrame":12},"Tricuspid annular plane systolic excursion (TAPSE)","Mean TAPSE value (mm) measured by echocardiography.",{"measure":24,"description":25,"timeFrame":12},"Right ventricular fractional area change","Mean right ventricular fractional area change (%) measured by echocardiography.",null,{"allocation":26,"interventionModel":26,"interventionModelDescription":26,"primaryPurpose":26,"observationalModel":28,"timePerspective":29,"maskingInfo":26},"CASE_ONLY","CROSS_SECTIONAL","Myeloproliferative neoplasms (MPNs) are associated with an increased risk of pulmonary hypertension and right ventricular dysfunction. This observational study will include adults with confirmed polycythemia vera, essential thrombocythemia, or primary myelofibrosis.\n\nAll participants will undergo clinical assessment, laboratory evaluation, and echocardiography to assess pulmonary artery systolic pressure and right ventricular systolic function (TAPSE, FAC, and tissue Doppler S').","Adult patients with confirmed myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, or primary myelofibrosis) attending the Hematology Unit and Critical Care Department at Assiut University Hospital.",[33],{"label":34,"type":26,"description":35,"interventionNames":26},"Single cohort: Patients with myeloproliferative neoplasms","Adult patients with myeloproliferative neoplasms who will undergo clinical, laboratory, and echocardiographic assessment for pulmonary hypertension and right ventricular dysfunction.",[37],{"name":38,"affiliation":39,"role":40},"Refaat f abdel all, prof","Critical care unit Internal Medicine Department, Assiut University Hospitals","STUDY_CHAIR",[42],{"name":43,"role":44,"phone":45,"phoneExt":26,"email":46},"Esraa M Ahmed, Resident","CONTACT","+20 10 99071931","esraamedhat449@gmail.com",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Esraa medhat Ahmed","Resident Physician","100657101","pulmonary-hypertension-and-rv-dysfunction-in-myeloproliferative-neoplasms-100657101",false,"NCT07834918","Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms","Clinical and Hematologic Risk Factors of Right Ventricular Dysfunction and Pulmonary Hypertension in Myeloproliferative Neoplasms","Inclusion Criteria:\n\n* \\- Age 18 years or older\n* Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, or primary myelofibrosis)\n* Stable clinical condition\n* Written informed consent\n\nExclusion Criteria:\n\n* \\- Significant left-sided valvular heart disease\n* Congenital heart disease\n* COPD or interstitial lung disease causing pulmonary hypertension\n* Poor echocardiographic window","ALL","18 Years",{"count":61,"type":62},145,"ESTIMATED","OBSERVATIONAL","This cross-sectional study aims to determine the prevalence of pulmonary hypertension and right ventricular dysfunction in patients with myeloproliferative neoplasms and to identify associated clinical and hematologic factors.",[66,67,68],"Myeloproliferative Neoplasm","Right Ventricular Dysfunction","Pulmonary Hypertension",[70,71,72,73,74],"Assiut","Echocardiography","Right ventricular dysfunction","Myeloproliferative neoplasm","Pulmonary hypertension","NOT_YET_RECRUITING","2026-09-17",{"date":78,"type":79},"2026-09-22","ACTUAL",{"date":81,"type":62},"2026-09-20",{"date":83,"type":62},"2028-03-10",{"name":5,"class":6}]